Certara Inc (CERT)

$11.45 -$0.26 (-2.22%) 12:03 PM 12/13/24
NASDAQ | $USD | Health Information Services

Stock Data

  • Market Cap

    $1.75B
  • Day's Range

    $11.29 - $11.83
  • Volume

    1,453,250
  • 52 Week Low / High

    $9.41 - $19.87
  • PE Ratio

    -
  • PEG Ratio

    -
  • Dividend Frequency

    -

CERT's Dividend
-
Amount
-
Dividend Yield
Nov 30
Payment Date
-
Annual Dividend Amount
Dividend Streak
Hypothetical 10k Investment Jan 1, 2020
Capital Growth
Dividend Return to Date
Dividend Payout year Est.
Expenses
Total Return
Total Return %
Analyists Ranking
4
Strong Buy
0
Buy
7
Hold
0
Sell
0
Strong Sell
$18.57
Target Price

Company News

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

Similar Stocks

Want to be notified on dividend changes?

Start manging your portfolio today.

Sign up for free